Access the full text.
Sign up today, get DeepDyve free for 14 days.
( Allen JA , Pasnoor M , Dimachkie MM , et al. Quantifying treatment‐related fluctuations in CIDP: results of the GRIPPER study. Neurology. 2021;96(14):e1876‐e1886. doi:10.1212/WNL.0000000000011703 (published Online First: 2021/02/18).33593867)
Allen JA , Pasnoor M , Dimachkie MM , et al. Quantifying treatment‐related fluctuations in CIDP: results of the GRIPPER study. Neurology. 2021;96(14):e1876‐e1886. doi:10.1212/WNL.0000000000011703 (published Online First: 2021/02/18).33593867Allen JA , Pasnoor M , Dimachkie MM , et al. Quantifying treatment‐related fluctuations in CIDP: results of the GRIPPER study. Neurology. 2021;96(14):e1876‐e1886. doi:10.1212/WNL.0000000000011703 (published Online First: 2021/02/18).33593867, Allen JA , Pasnoor M , Dimachkie MM , et al. Quantifying treatment‐related fluctuations in CIDP: results of the GRIPPER study. Neurology. 2021;96(14):e1876‐e1886. doi:10.1212/WNL.0000000000011703 (published Online First: 2021/02/18).33593867
O. Mielke, V. Bril, D. Cornblath, J. Lawo, N. Geloven, H. Hartung, Richard Lewis, I. Merkies, G. Sobue, B. Durn, A. Shebl, I. Schaik, A. Damm, A. Sabet, K. George, L. Roberts, R. Carne, S. Blum, R. Henderson, P. Damme, J. Demeestere, S. Larue, C. D'Amour, P. Kunc, M. Valis, J. Sussova, T. Kalous, R. Taláb, M. Bednar, T. Toomsoo, I. Rubanovits, K. Gross-Paju, U. Sorro, M. Saarela, M. Auranen, J. Pouget, S. Attarian, G. Masson, A. Wielanek-Bachelet, C. Desnuelle, E. Delmont, P. Clavelou, D. Aufauvre, J. Schmidt, J. Zschuentzsch, C. Sommer, D. Kramer, O. Hoffmann, C. Goerlitz, J. Haas, M. Chatzopoulos, R. Yoon, R. Gold, P. Berlit, A. Jaspert‐Grehl, D. Liebetanz, A. Kutschenko, M. Stangel, C. Trebst, P. Baum, F. Bergh, J. Klehmet, A. Meisel, F. Klostermann, J. Oechtering, H. Lehmann, M. Schroeter, T. Hagenacker, D. Mueller, A. Sperfeld, F. Bethke, V. Drory, A. Algom, D. Yarnitsky, B. Murinson, A. Muzio, F. Ciccocioppo, S. Sorbi, S. Matà, A. Schenone, M. Grandis, G. Lauria, D. Cazzato, G. Antonini, S. Morino, D. Cocito, M. Zibetti, T. Yokota, T. Ohkubo, T. Kanda, M. Kawai, K. Kaida, H. Onoue, S. Kuwabara, M. Mori, M. Iijima, K. Ohyama, M. Baba, M. Tomiyama, K. Nishiyama, T. Akutsu, K. Yokoyama, K. Kanai, I. Schaik, F. Eftimov, N. Notermans, N. Visser, C. Faber, J. Hoeijmakers, K. Rejdak, U. Chyrchel-Paszkiewicz, C. Pons, M. Antonia, J. Gamez, M. Salvadó, C. Infante, S. Benitez, M. Lunn, J. Morrow, D. Gosal, T. Lavin, I. Melamed, A. Testori, S. Ajroud-Driss, D. Menichella, E. Simpson, E. Lai, M. Dimachkie, R. Barohn, S. Beydoun, H. Johl, D. Lange, A. Shtilbans, S. Muley, S. Ladha, M. Freimer, J. Kissel, N. Latov, R. Chin, E. Ubogu, S. Mumfrey, T. Rao, P. MacDonald, K. Sharma, G. González, J. Allen, D. Walk, L. Hobson‐Webb, K. Gable (2019)
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra studyJournal of the Peripheral Nervous System, 24
( Beaton DE , Boers M , Wells GA . Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol. 2002;14(2):109‐114. doi:10.1097/00002281-200203000-00006 11845014)
Beaton DE , Boers M , Wells GA . Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol. 2002;14(2):109‐114. doi:10.1097/00002281-200203000-00006 11845014Beaton DE , Boers M , Wells GA . Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol. 2002;14(2):109‐114. doi:10.1097/00002281-200203000-00006 11845014, Beaton DE , Boers M , Wells GA . Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol. 2002;14(2):109‐114. doi:10.1097/00002281-200203000-00006 11845014
( White D , Englezou C , Rajabally YA . Patient perceptions of outcome measures in chronic inflammatory demyelinating polyneuropathy: a study of the inflammatory Rasch‐built overall disability scale. Eur J Neurol. 2021;28(8):2596‐2602. doi:10.1111/ene.14907 (published Online First: 2021/05/11).33969583)
White D , Englezou C , Rajabally YA . Patient perceptions of outcome measures in chronic inflammatory demyelinating polyneuropathy: a study of the inflammatory Rasch‐built overall disability scale. Eur J Neurol. 2021;28(8):2596‐2602. doi:10.1111/ene.14907 (published Online First: 2021/05/11).33969583White D , Englezou C , Rajabally YA . Patient perceptions of outcome measures in chronic inflammatory demyelinating polyneuropathy: a study of the inflammatory Rasch‐built overall disability scale. Eur J Neurol. 2021;28(8):2596‐2602. doi:10.1111/ene.14907 (published Online First: 2021/05/11).33969583, White D , Englezou C , Rajabally YA . Patient perceptions of outcome measures in chronic inflammatory demyelinating polyneuropathy: a study of the inflammatory Rasch‐built overall disability scale. Eur J Neurol. 2021;28(8):2596‐2602. doi:10.1111/ene.14907 (published Online First: 2021/05/11).33969583
( van Nes SI , Vanhoutte EK , van Doorn PA , et al. Rasch‐built overall disability scale (R‐ODS) for immune‐mediated peripheral neuropathies. Neurology. 2011;76(4):337‐345.21263135)
van Nes SI , Vanhoutte EK , van Doorn PA , et al. Rasch‐built overall disability scale (R‐ODS) for immune‐mediated peripheral neuropathies. Neurology. 2011;76(4):337‐345.21263135van Nes SI , Vanhoutte EK , van Doorn PA , et al. Rasch‐built overall disability scale (R‐ODS) for immune‐mediated peripheral neuropathies. Neurology. 2011;76(4):337‐345.21263135, van Nes SI , Vanhoutte EK , van Doorn PA , et al. Rasch‐built overall disability scale (R‐ODS) for immune‐mediated peripheral neuropathies. Neurology. 2011;76(4):337‐345.21263135
(2022)
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revisionJournal of the Peripheral Nervous System, 27
S. Nes, E. Vanhoutte, P. Doorn, M. Hermans, M. Bakkers, K. Kuitwaard, C. Faber, I. Merkies (2011)
Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathiesNeurology, 76
D. Beaton, M. Boers, G. Wells (2002)
Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research.Current opinion in rheumatology, 14 2
R. Lewis, D. Cornblath, H. Hartung, G. Sobue, J. Lawo, O. Mielke, B. Durn, V. Bril, I. Merkies, P. Bassett, Alexa Cleasby, I. Schaik (2020)
Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic reviewJournal of the Peripheral Nervous System, 25
( de Vet HC , Terwee CB . The minimal detectable change should not replace the minimal important difference. J Clin Epidemiol. 2010;63(7):804‐805; author reply 806. doi:10.1016/j.jclinepi.2009.12.015 (published Online First: April 20, 2010).20399609)
de Vet HC , Terwee CB . The minimal detectable change should not replace the minimal important difference. J Clin Epidemiol. 2010;63(7):804‐805; author reply 806. doi:10.1016/j.jclinepi.2009.12.015 (published Online First: April 20, 2010).20399609de Vet HC , Terwee CB . The minimal detectable change should not replace the minimal important difference. J Clin Epidemiol. 2010;63(7):804‐805; author reply 806. doi:10.1016/j.jclinepi.2009.12.015 (published Online First: April 20, 2010).20399609, de Vet HC , Terwee CB . The minimal detectable change should not replace the minimal important difference. J Clin Epidemiol. 2010;63(7):804‐805; author reply 806. doi:10.1016/j.jclinepi.2009.12.015 (published Online First: April 20, 2010).20399609
( van Schaik IN , Bril V , van Geloven N , et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35‐46. doi:10.1016/s1474-4422(17)30378-2 29122523)
van Schaik IN , Bril V , van Geloven N , et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35‐46. doi:10.1016/s1474-4422(17)30378-2 29122523van Schaik IN , Bril V , van Geloven N , et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35‐46. doi:10.1016/s1474-4422(17)30378-2 29122523, van Schaik IN , Bril V , van Geloven N , et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35‐46. doi:10.1016/s1474-4422(17)30378-2 29122523
R. Keh, D. Selby, Sam Jones, D. Gosal, T. Lavin, James Lilleker, A. Carr, M. Lunn (2021)
Predicting long‐term trends in inflammatory neuropathy outcome measures using latent class modellingJournal of the Peripheral Nervous System, 27
PH.D. YOUDEN (1950)
Index for rating diagnostic testsCancer, 3
( Rajabally YA , Afzal S , Ghasemi M . Minimal important differences and self‐identifying treatment response in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2021;64(1):37‐42. doi:10.1002/mus.27250 (published Online First: 2021/04/10).33835480)
Rajabally YA , Afzal S , Ghasemi M . Minimal important differences and self‐identifying treatment response in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2021;64(1):37‐42. doi:10.1002/mus.27250 (published Online First: 2021/04/10).33835480Rajabally YA , Afzal S , Ghasemi M . Minimal important differences and self‐identifying treatment response in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2021;64(1):37‐42. doi:10.1002/mus.27250 (published Online First: 2021/04/10).33835480, Rajabally YA , Afzal S , Ghasemi M . Minimal important differences and self‐identifying treatment response in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2021;64(1):37‐42. doi:10.1002/mus.27250 (published Online First: 2021/04/10).33835480
( Norman GR , Stratford P , Regehr G . Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol. 1997;80(8):869‐879. doi:10.1016/s0895-4356(97)00097-8 )
Norman GR , Stratford P , Regehr G . Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol. 1997;80(8):869‐879. doi:10.1016/s0895-4356(97)00097-8Norman GR , Stratford P , Regehr G . Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol. 1997;80(8):869‐879. doi:10.1016/s0895-4356(97)00097-8 , Norman GR , Stratford P , Regehr G . Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol. 1997;80(8):869‐879. doi:10.1016/s0895-4356(97)00097-8
S. Kunte (2000)
Statistical computingResonance, 5
( Keh RYS , Selby DA , Jones S , et al. Predicting long‐term trends in inflammatory neuropathy outcome measures using latent class modelling. J Peripher Nerv Syst. 2021;27:84‐93. doi:10.1111/jns.12481 )
Keh RYS , Selby DA , Jones S , et al. Predicting long‐term trends in inflammatory neuropathy outcome measures using latent class modelling. J Peripher Nerv Syst. 2021;27:84‐93. doi:10.1111/jns.12481Keh RYS , Selby DA , Jones S , et al. Predicting long‐term trends in inflammatory neuropathy outcome measures using latent class modelling. J Peripher Nerv Syst. 2021;27:84‐93. doi:10.1111/jns.12481 , Keh RYS , Selby DA , Jones S , et al. Predicting long‐term trends in inflammatory neuropathy outcome measures using latent class modelling. J Peripher Nerv Syst. 2021;27:84‐93. doi:10.1111/jns.12481
T. Draak, B. Greef, C. Faber, I. Merkies (2019)
The minimum clinically important difference: which direction to takeEuropean Journal of Neurology, 26
A. Wright, Joseph Hannon, E. Hegedus, A. Kavchak (2012)
Clinimetrics corner: a closer look at the minimal clinically important difference (MCID)Journal of Manual & Manipulative Therapy, 20
P. Doneddu, Daniele Mandia, Francesco Gentile, F. Gallia, G. Liberatore, F. Terenghi, M. Ruiz, E. Nobile‐Orazio (2020)
Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy.Journal of the peripheral nervous system : JPNS
G. Norman, P. Stratford, G. Regehr (1997)
Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach.Journal of clinical epidemiology, 50 8
( Revicki D , Hays RD , Cella D , Sloan J . Recommended methods for determining responsiveness and minimally important differences for patient‐reported outcomes. J Clin Epidemiol. 2008;61(2):102‐109. doi:10.1016/j.jclinepi.2007.03.012 (published Online First: 2008/01/08).18177782)
Revicki D , Hays RD , Cella D , Sloan J . Recommended methods for determining responsiveness and minimally important differences for patient‐reported outcomes. J Clin Epidemiol. 2008;61(2):102‐109. doi:10.1016/j.jclinepi.2007.03.012 (published Online First: 2008/01/08).18177782Revicki D , Hays RD , Cella D , Sloan J . Recommended methods for determining responsiveness and minimally important differences for patient‐reported outcomes. J Clin Epidemiol. 2008;61(2):102‐109. doi:10.1016/j.jclinepi.2007.03.012 (published Online First: 2008/01/08).18177782, Revicki D , Hays RD , Cella D , Sloan J . Recommended methods for determining responsiveness and minimally important differences for patient‐reported outcomes. J Clin Epidemiol. 2008;61(2):102‐109. doi:10.1016/j.jclinepi.2007.03.012 (published Online First: 2008/01/08).18177782
( Doneddu PE , Mandia D , Gentile F , et al. Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy. J Peripher Nerv Syst. 2020;25(3):238‐246. doi:10.1111/jns.12396 (published Online First: 2020/05/30).32470190)
Doneddu PE , Mandia D , Gentile F , et al. Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy. J Peripher Nerv Syst. 2020;25(3):238‐246. doi:10.1111/jns.12396 (published Online First: 2020/05/30).32470190Doneddu PE , Mandia D , Gentile F , et al. Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy. J Peripher Nerv Syst. 2020;25(3):238‐246. doi:10.1111/jns.12396 (published Online First: 2020/05/30).32470190, Doneddu PE , Mandia D , Gentile F , et al. Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy. J Peripher Nerv Syst. 2020;25(3):238‐246. doi:10.1111/jns.12396 (published Online First: 2020/05/30).32470190
( Lewis RA , Cornblath DR , Hartung HP , et al. Placebo effect in chronic inflammatory demyelinating polyneuropathy: the PATH study and a systematic review. J Peripher Nerv Syst. 2020;25(3):230‐237. doi:10.1111/jns.12402 (published Online First: 2020/07/07).32627277)
Lewis RA , Cornblath DR , Hartung HP , et al. Placebo effect in chronic inflammatory demyelinating polyneuropathy: the PATH study and a systematic review. J Peripher Nerv Syst. 2020;25(3):230‐237. doi:10.1111/jns.12402 (published Online First: 2020/07/07).32627277Lewis RA , Cornblath DR , Hartung HP , et al. Placebo effect in chronic inflammatory demyelinating polyneuropathy: the PATH study and a systematic review. J Peripher Nerv Syst. 2020;25(3):230‐237. doi:10.1111/jns.12402 (published Online First: 2020/07/07).32627277, Lewis RA , Cornblath DR , Hartung HP , et al. Placebo effect in chronic inflammatory demyelinating polyneuropathy: the PATH study and a systematic review. J Peripher Nerv Syst. 2020;25(3):230‐237. doi:10.1111/jns.12402 (published Online First: 2020/07/07).32627277
I. Merkies, S. Nes, Kim Hanna, Richard Hughes, C. Deng (2010)
Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevanceJournal of Neurology, Neurosurgery & Psychiatry, 81
(2020)
Daily grip strength response to IVIg in chronic immune neuropathies
( Van den Bergh PYK , van Doorn PA , Hadden RDM , et al. European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force‐second revision. J Peripher Nerv Syst. 2021;26(3):242‐268. doi:10.1111/jns.12455 (published Online First: 2021/06/05).34085743)
Van den Bergh PYK , van Doorn PA , Hadden RDM , et al. European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force‐second revision. J Peripher Nerv Syst. 2021;26(3):242‐268. doi:10.1111/jns.12455 (published Online First: 2021/06/05).34085743Van den Bergh PYK , van Doorn PA , Hadden RDM , et al. European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force‐second revision. J Peripher Nerv Syst. 2021;26(3):242‐268. doi:10.1111/jns.12455 (published Online First: 2021/06/05).34085743, Van den Bergh PYK , van Doorn PA , Hadden RDM , et al. European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force‐second revision. J Peripher Nerv Syst. 2021;26(3):242‐268. doi:10.1111/jns.12455 (published Online First: 2021/06/05).34085743
M. Adrichem, I. Lucke, A. Vrancken, H. Goedee, L. Wieske, M. Dijkgraaf, N. Voermans, N. Notermans, C. Faber, L. Visser, K. Kuitwaard, P. Doorn, I. Merkies, R. Haan, I. Schaik, F. Eftimov (2022)
Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathyBrain, 145
E. Vanhoutte, T. Draak, K. Gorson, S. Nes, J. Hoeijmakers, W. Pol, N. Notermans, Richard Lewis, E. Nobile‐Orazio, J. Léger, P. Bergh, G. Lauria, V. Bril, H. Katzberg, M. Lunn, J. Pouget, A. Kooi, A. Hahn, P. Doorn, D. Cornblath, L. Berg, C. Faber, I. Merkies (2015)
Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparisonJournal of the Peripheral Nervous System, 20
Bethesda (MD): National Library of Medicine (US)
E. Vanhoutte, C. Faber, I. Merkies (2013)
196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8–10 February 2013, Naarden, The NetherlandsNeuromuscular Disorders, 23
T. Draak, Mariëlle Pruppers, S. Nes, E. Vanhoutte, M. Bakkers, K. Gorson, W. Pol, R. Lewis, N. Notermans, E. Nobile‐Orazio, J. Léger, P. Bergh, G. Lauria, V. Bril, H. Katzberg, M. Lunn, J. Pouget, A. Kooi, L. Berg, P. Doorn, D. Cornblath, A. Hahn, C. Faber, I. Merkies (2015)
Grip strength comparison in immune‐mediated neuropathies: Vigorimeter vs. JamarJournal of the Peripheral Nervous System, 20
( Draak TH , Pruppers MHJ , van Nes SI , et al. Grip strength comparison in immune‐mediated neuropathies Vigorimeter vs Jamar. J Peripher Nerv Syst. 2015;20:269‐276. doi:10.1111/jns.12126 26115516)
Draak TH , Pruppers MHJ , van Nes SI , et al. Grip strength comparison in immune‐mediated neuropathies Vigorimeter vs Jamar. J Peripher Nerv Syst. 2015;20:269‐276. doi:10.1111/jns.12126 26115516Draak TH , Pruppers MHJ , van Nes SI , et al. Grip strength comparison in immune‐mediated neuropathies Vigorimeter vs Jamar. J Peripher Nerv Syst. 2015;20:269‐276. doi:10.1111/jns.12126 26115516, Draak TH , Pruppers MHJ , van Nes SI , et al. Grip strength comparison in immune‐mediated neuropathies Vigorimeter vs Jamar. J Peripher Nerv Syst. 2015;20:269‐276. doi:10.1111/jns.12126 26115516
H. Vet, C. Terwee (2010)
The minimal detectable change should not replace the minimal important difference.Journal of clinical epidemiology, 63 7
Y. Rajabally, Majid Ghasemi (2020)
Comparative value and determinants of suitability of outcome measures in treated chronic inflammatory demyelinating polyneuropathyMuscle & Nerve, 61
J. Bland, Douglas Altman (1986)
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 327
Roman Jaeschke, J. Singer, G. Guyatt (1989)
Measurement of health status. Ascertaining the minimal clinically important difference.Controlled clinical trials, 10 4
( National Library of Medicine . Rituximab in chronic inflammatory demyelinating polyneuropathy. Clinicaltrials.gov [Internet]. 2000 Feb 29. Identifier: NCT04480450. July 21, 2020. Bethesda (MD): National Library of Medicine (US). Accessed May 12, 2022. https://clinicaltrials.gov/ct2/show/NCT04480450 )
National Library of Medicine . Rituximab in chronic inflammatory demyelinating polyneuropathy. Clinicaltrials.gov [Internet]. 2000 Feb 29. Identifier: NCT04480450. July 21, 2020. Bethesda (MD): National Library of Medicine (US). Accessed May 12, 2022. https://clinicaltrials.gov/ct2/show/NCT04480450National Library of Medicine . Rituximab in chronic inflammatory demyelinating polyneuropathy. Clinicaltrials.gov [Internet]. 2000 Feb 29. Identifier: NCT04480450. July 21, 2020. Bethesda (MD): National Library of Medicine (US). Accessed May 12, 2022. https://clinicaltrials.gov/ct2/show/NCT04480450 , National Library of Medicine . Rituximab in chronic inflammatory demyelinating polyneuropathy. Clinicaltrials.gov [Internet]. 2000 Feb 29. Identifier: NCT04480450. July 21, 2020. Bethesda (MD): National Library of Medicine (US). Accessed May 12, 2022. https://clinicaltrials.gov/ct2/show/NCT04480450
( Youden WJ . Index for rating diagnostic tests. Cancer. 1950;3(1):32‐35. doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3 15405679)
Youden WJ . Index for rating diagnostic tests. Cancer. 1950;3(1):32‐35. doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3 15405679Youden WJ . Index for rating diagnostic tests. Cancer. 1950;3(1):32‐35. doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3 15405679, Youden WJ . Index for rating diagnostic tests. Cancer. 1950;3(1):32‐35. doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3 15405679
( Vanhoutte EK , Latov N , Deng C , et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG‐‐the ICE study. Eur J Neurol. 2013;20(5):748‐755. doi:10.1111/j.1468-1331.2012.03851.x (published Online First: 2012/08/16).22891893)
Vanhoutte EK , Latov N , Deng C , et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG‐‐the ICE study. Eur J Neurol. 2013;20(5):748‐755. doi:10.1111/j.1468-1331.2012.03851.x (published Online First: 2012/08/16).22891893Vanhoutte EK , Latov N , Deng C , et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG‐‐the ICE study. Eur J Neurol. 2013;20(5):748‐755. doi:10.1111/j.1468-1331.2012.03851.x (published Online First: 2012/08/16).22891893, Vanhoutte EK , Latov N , Deng C , et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG‐‐the ICE study. Eur J Neurol. 2013;20(5):748‐755. doi:10.1111/j.1468-1331.2012.03851.x (published Online First: 2012/08/16).22891893
(2021)
Quantifying treatmentrelated fluctuations in CIDP: results of the GRIPPER study. Neurology. 2021;96(14):e1876-e1886. doi:10.1212/WNL.0000000000011703 (published Online First: 2021/02/18)
D. Revicki, R. Hays, D. Cella, J. Sloan (2008)
Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes.Journal of clinical epidemiology, 61 2
Quantifying Treatment-Related Fluctuations in CIDP Results of the GRIPPER Study
I. Schaik, V. Bril, N. Geloven, H. Hartung, R. Lewis, G. Sobue, J. Lawo, M. Praus, O. Mielke, B. Durn, D. Cornblath, I. Merkies (2018)
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Neurology, 17
( Peric S , Bozovic I , Pruppers MHJ , et al. Validation of the Serbian version of inflammatory Rasch‐built overall disability scale in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2019;24(3):260‐267. doi:10.1111/jns.12343 (published Online First: 2019/08/10).31397933)
Peric S , Bozovic I , Pruppers MHJ , et al. Validation of the Serbian version of inflammatory Rasch‐built overall disability scale in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2019;24(3):260‐267. doi:10.1111/jns.12343 (published Online First: 2019/08/10).31397933Peric S , Bozovic I , Pruppers MHJ , et al. Validation of the Serbian version of inflammatory Rasch‐built overall disability scale in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2019;24(3):260‐267. doi:10.1111/jns.12343 (published Online First: 2019/08/10).31397933, Peric S , Bozovic I , Pruppers MHJ , et al. Validation of the Serbian version of inflammatory Rasch‐built overall disability scale in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2019;24(3):260‐267. doi:10.1111/jns.12343 (published Online First: 2019/08/10).31397933
T. Draak, E. Vanhoutte, S. Nes, K. Gorson, W. Pol, N. Notermans, E. Nobile‐Orazio, J. Léger, P. Bergh, P. Bergh, G. Lauria, V. Bril, H. Katzberg, M. Lunn, J. Pouget, A. Kooi, A. Hahn, P. Doorn, D. Cornblath, L. Berg, C. Faber, I. Merkies (2014)
Changing outcome in inflammatory neuropathiesNeurology, 83
( R Foundation for Statistical Computing . R: a language and environment for statistical computing . R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/ [program]. 2014.)
R Foundation for Statistical Computing . R: a language and environment for statistical computing . R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/ [program]. 2014.R Foundation for Statistical Computing . R: a language and environment for statistical computing . R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/ [program]. 2014., R Foundation for Statistical Computing . R: a language and environment for statistical computing . R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/ [program]. 2014.
S. Perić, I. Bozovic, Mariëlle Pruppers, B. Bjelica, Z. Stevic, C. Faber, I. Merkies, I. Basta (2019)
Validation of the Serbian version of inflammatory Rasch‐built overall disability scale in patients with chronic inflammatory demyelinating polyradiculoneuropathyJournal of the Peripheral Nervous System, 24
( Bland JM , Altman DG . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;8(8476):307‐310.)
Bland JM , Altman DG . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;8(8476):307‐310.Bland JM , Altman DG . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;8(8476):307‐310., Bland JM , Altman DG . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;8(8476):307‐310.
( Adrichem ME , Lucke IM , Vrancken AFJ , et al. Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2022;awac054. doi:10.1093/brain/awac054 )
Adrichem ME , Lucke IM , Vrancken AFJ , et al. Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2022;awac054. doi:10.1093/brain/awac054Adrichem ME , Lucke IM , Vrancken AFJ , et al. Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2022;awac054. doi:10.1093/brain/awac054 , Adrichem ME , Lucke IM , Vrancken AFJ , et al. Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2022;awac054. doi:10.1093/brain/awac054
( Merkies IS , van Nes SI , Hanna K , et al. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry. 2010;81(11):1194‐1199. doi:10.1136/jnnp.2009.194324 (published Online First: 2010/07/22).20647554)
Merkies IS , van Nes SI , Hanna K , et al. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry. 2010;81(11):1194‐1199. doi:10.1136/jnnp.2009.194324 (published Online First: 2010/07/22).20647554Merkies IS , van Nes SI , Hanna K , et al. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry. 2010;81(11):1194‐1199. doi:10.1136/jnnp.2009.194324 (published Online First: 2010/07/22).20647554, Merkies IS , van Nes SI , Hanna K , et al. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry. 2010;81(11):1194‐1199. doi:10.1136/jnnp.2009.194324 (published Online First: 2010/07/22).20647554
JA Allen, ISJ Merkies, RA Lewis (2020)
Monitoring clinical course and treatment response in chronic inflammatory demyelinating polyneuropathy during routine care, 77
E. Vanhoutte, N. Latov, C. Deng, K. Hanna, R. Hughes, V. Bril, M. Dalakas, P. Donofrio, P. Doorn, H. Hartung, I. Merkies (2013)
Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG – the ICE studyEuropean Journal of Neurology, 20
Daniel White, C. Englezou, Y. Rajabally (2021)
Patient perceptions of outcome measures in chronic inflammatory demyelinating polyneuropathy: A study of the Inflammatory Rasch‐built Overall Disability ScaleEuropean Journal of Neurology, 28
( Mielke O , Bril V , Cornblath DR , et al. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: results from the pre‐randomization phase of the polyneuropathy and treatment with Hizentra study. J Peripher Nerv Syst. 2019;24(1):72‐79. doi:10.1111/jns.12303 (published Online First: 2019/01/24).30672067)
Mielke O , Bril V , Cornblath DR , et al. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: results from the pre‐randomization phase of the polyneuropathy and treatment with Hizentra study. J Peripher Nerv Syst. 2019;24(1):72‐79. doi:10.1111/jns.12303 (published Online First: 2019/01/24).30672067Mielke O , Bril V , Cornblath DR , et al. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: results from the pre‐randomization phase of the polyneuropathy and treatment with Hizentra study. J Peripher Nerv Syst. 2019;24(1):72‐79. doi:10.1111/jns.12303 (published Online First: 2019/01/24).30672067, Mielke O , Bril V , Cornblath DR , et al. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: results from the pre‐randomization phase of the polyneuropathy and treatment with Hizentra study. J Peripher Nerv Syst. 2019;24(1):72‐79. doi:10.1111/jns.12303 (published Online First: 2019/01/24).30672067
Jeffrey Allen, I. Merkies, R. Lewis (2020)
Monitoring Clinical Course and Treatment Response in Chronic Inflammatory Demyelinating Polyneuropathy During Routine Care: A Review of Clinical and Laboratory Assessment Measures.JAMA neurology
( Wright A , Hannon J , Hegedus EJ , Kavchak AE . Clinimetrics corner: a closer look at the minimal clinically important difference (MCID). J Man Manip Ther. 2012;20(3):160‐166. doi:10.1179/2042618612Y.0000000001 (published Online First: 2013/08/02).23904756)
Wright A , Hannon J , Hegedus EJ , Kavchak AE . Clinimetrics corner: a closer look at the minimal clinically important difference (MCID). J Man Manip Ther. 2012;20(3):160‐166. doi:10.1179/2042618612Y.0000000001 (published Online First: 2013/08/02).23904756Wright A , Hannon J , Hegedus EJ , Kavchak AE . Clinimetrics corner: a closer look at the minimal clinically important difference (MCID). J Man Manip Ther. 2012;20(3):160‐166. doi:10.1179/2042618612Y.0000000001 (published Online First: 2013/08/02).23904756, Wright A , Hannon J , Hegedus EJ , Kavchak AE . Clinimetrics corner: a closer look at the minimal clinically important difference (MCID). J Man Manip Ther. 2012;20(3):160‐166. doi:10.1179/2042618612Y.0000000001 (published Online First: 2013/08/02).23904756
Jeffrey Allen, F. Eftimov, L. Querol (2021)
Outcome measures and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathy: from research to clinical practiceExpert Review of Neurotherapeutics, 21
( Jaeschke R , Singer J , Guyatt GH . Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407‐415. doi:10.1016/0197-2456(89)90005-6 2691207)
Jaeschke R , Singer J , Guyatt GH . Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407‐415. doi:10.1016/0197-2456(89)90005-6 2691207Jaeschke R , Singer J , Guyatt GH . Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407‐415. doi:10.1016/0197-2456(89)90005-6 2691207, Jaeschke R , Singer J , Guyatt GH . Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407‐415. doi:10.1016/0197-2456(89)90005-6 2691207
Y. Rajabally, S. Afzal, Majid Ghasemi (2021)
Minimal important differences and self‐identifying treatment response in chronic inflammatory demyelinating polyneuropathyMuscle & Nerve, 64
It is unclear whether frequently used cutoff values for outcome measures defining minimal clinically important differences (MCIDs) can accurately identify meaningful deterioration in chronic inflammatory demyelinating polyneuropathy (CIDP). We used data from the immunoglobulin overtreatment in CIDP (IOC) trial, in which 60 clinically stable patients with CIDP were randomized to intravenous immunoglobulin (IVIg) withdrawal or continuation. We calculated change scores of the Inflammatory Rasch‐Built Overall Disability Scale (I‐RODS), grip strength, and Medical Research Council‐sum score (MRC‐SS) and classified visits based on a treatment anchor (ie, decision to restart/increase treatment after reaching a predefined early endpoint of deterioration). The variability of scores in patients without deterioration was calculated using the limits of agreement. We defined optimized MCIDs for deterioration and specific combinations of MCIDs from different outcome measures, and subsequently calculated the accuracies of the (combined) MCIDs. Substantial variability was found in scores of the I‐RODS, grip strength and MRC‐SS in patients without deterioration over time, and most MCIDs were within the limits of the variability observed in patients without deterioration. Some MCID cut‐offs were insensitive but highly specific for detecting deterioration, for example, the MCID‐SE of −1.96 of the I‐RODS and −2 point on the MRC‐SS. Others were sensitive, but less specific, for example, −4 centiles of the I‐RODS. Some combined MCIDs resulted in high specificities and moderate sensitivities. Our results suggest that clinically important deterioration cannot be distinguished from variability over time with currently used MCIDs on the individual level. Combinations of MCIDs might improve the accuracy of determining deterioration, but this needs validation.
Journal of the Peripheral Nervous System – Wiley
Published: Jun 1, 2022
Keywords: chronic inflammatory demyelinating polyneuropathy; minimum important difference; outcome measures
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.